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Summary We report a case of 45-year-old man, who was diagnosed with arrhythmo-
genic right ventricular cardiomyopathy (ARVC) and presented with right ventricular (RV)
enlargement with a global decrease in RV contractility accompanied by impairment of left
ventricular function. He was placed on the heart transplant waiting list. Endomyocardial
biopsy from RV septal wall did not show any evidence of sarcoidosis or inﬂammatory change.
Four years after he was put on the heart transplant waiting list, a computed tomography
chest scan for the purpose of anatomical evaluation for coronary sinus prior to biventric-
ular pacing lead implantation incidentally showed bilateral hilar lymphadenopathy, which
suggested the possibility of sarcoidosis. Biopsy of the inguinal lymph node pathologically
was consistent with sarcoidosis. The 2[18F]ﬂuoro-2-deoxy-D-glucose positron emission tomog-
raphy scanning (FDG-PET) demonstrated intense uptake in the myocardium, and the patient
was ﬁnally diagnosed as having cardiac sarcoidosis. After steroid treatment, the abnor-
mal FDG-PET uptake disappeared. The patient therefore represented a case of cardiac
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sarcoidosis masquerading as ARVC. It should be recognized that RV involvement is one of the
coidosis.
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45-year-old man without signiﬁcant past medical history
as admitted to hospital 6 years ago due to exertional
yspnea. Two-dimensional transthoracic echocardiography
emonstrated dilated left ventricle (LV) with decreased
ontraction and concentric hypertrophy. Coronary angiog-
aphy was normal, and a left ventriculogram showed diffuse
ypokinesis. The endomyocardial biopsy obtained from right
entricular septal wall showed severe ﬁbrosis and sporadic
ypertrophied myocytes without any inﬂammatory changes.
he LV ejection fraction was 7% at that time, and he
as diagnosed with the dilated phase of hypertrophic car-
iomyopathy at this point, and has since been undergoing
-blocker (carvedilol) therapy.
However, his heart failure symptoms of New York Heart
ssociation class II to III had not been improved in spite
f -blocker therapy, therefore, he was transferred to our
ospital for heart transplant evaluation 2 years after the
nitial episode of admission due to heart failure. His physi-
al examination showed hepatomegaly with a small amount
f ascites. Two-dimensional transthoracic echocardiography
evealed signiﬁcant right ventricle (RV) enlargement with
markedly global decrease in RV contractility accompa-
ied by impairment of dilated LV contraction and severe
ricuspid regurgitation (Fig. 1). Gadolinium-enhanced car-
iovascular magnetic resonance imaging (MRI) revealed late
nhancement in biventricles (Fig. 2). The 24-h Holter elec-
rocardiogram monitoring showed non-sustained ventricular
achycardia with left bundle branch block morphology
nd more than 1000 polymorphic premature ventricular
eats. He was diagnosed with possible arrhythmogenic right
entricular cardiomyopathy (ARVC) on the basis of these
igure 1 Two-dimensional transthoracic echocardiography showin
ight ventricle; RA, right atrium.
t
h
h
1igure 2 Delayed gadolinium-enhanced MRI demonstrating
elayed enhancement of biventricles and signiﬁcant right ven-
ricular enlargement. LV, left ventricle; RV, right ventricle.
ndings. Since then, he has been on the heart transplant
aiting list.
Four years later, antiarrhythmic therapy (amiodarone)g signiﬁcant biventricular enlargement. LV, left ventricle; RV,
achycardia, however, despite amiodarone administration
e was readmitted because of exacerbation of chronic
eart failure, with a demonstration of atrial ﬂutter with
:1 atrio-ventricular conduction. The chest X-ray, 12-lead
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Table 1 Laboratory examination on the latest admission.
Laboratory
parameter
Results of
examination
Normal range
Hematological examination of peripheral blood
WBC (/L) 3.20× 103 4.40—9.00× 103
RBC (/L) 4.44× 106 4.20—5.50× 106
Hg (g/dL) 14.8 13.5—18.0
Ht (%) 43.5 36.0—54.0
Plat (/L) 122× 103 150—350× 103
Biochemical examination of serum
TP (g/dL) 60 6.7—8.3
Alb (g/dL) 3.2 4.0—5.0
Na (mEq/L) 141 138—146
K (mEq/L) 3.6 3.6—4.9
Cl (mEq/L) 108 99—109
CA (mEq/L) 9.1 8.7—10.3
T-Bil (mg/dL) 1.5 0.3—1.2
D-Bil (mg/dL) 0.7 0.0—0.4
AST (U/L) 29 13—33
ALT (U/L) 21 8—42
LDH (U/L) 184 119—229
ALP (U/L) 504 115—359
GTP (U/L) 329 1—47
CK (U/L) 53 62—287
BUN (mg/dL) 19 8.0—22.0
Cre (mg/dL) 0.97 0.60—1.10
UA (mg/L) 5.1 3.6—7.0
FBG (mg/dL) 77 80—112
HbA1c (%) 5.9 4.3—5.8
TC (mg/dL) 130 128—219
TG (mg/dL) 55 30—149
CRP (mg/dL) 0.08 0.0—0.3
BNP (pg/mL) 825.8 <20
Lysozyme (g/mL) 12.6 4.2—11.5
ACE (IU/L) 13.4 7.7—29.4
WBC: white blood cell count; RBC: red blood cell count; Hb:
hemoglobin; Hct: hematocrit; Plat: platelet count; TP: total
protein; Alb: albumin; Na: sodium; K: potassium; Cl: chlo-
ride; CA: calcium; T-Bil: total bilirubin: D-Bil: direct bilirubin;
AST: aspartate aminotransferase; ALT: alanine aminotransferase;
LDH: lactate dehydrogenase; ALP: alkaline phosphatase; GTP:
gamma-glutamyltransferase; CK: creatine phosphokinase; BUN:
blood urea nitrogen; Cre: creatinine; UA: uric acid; FBG: fasting
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pblood glucose; HbA1c: hemoglobin A1c; TC: total cholesterol;
TG: triglyceride; CRP: C-reactive protein; BNP: brain natriuretic
peptide; ACE: angiotensin-converting enzyme.
electrocardiogram just after admission demonstrating atrial
ﬂutter with 2:1 atrio-ventricular conduction, and 12-lead
electrocardiogram after cardioversion are shown in Fig. 3,
and the laboratory examination results on admission are
described in Table 1.
A cardiac resynchronization plus deﬁbrillator was then
implanted. Before the leads for resynchronization therapy
were implanted, a computed tomography scan of the chest
was performed with the aim of identifying the coronary
sinus. The computed tomography scan showed bilateral hilar
lymphadenopathy (Fig. 4(a)) suggesting the possibility of
sarcoidosis. Gallium-67 scintigraphy was then obtained to
evaluate the activity and to conﬁrm a suspicion of sarcoido-
w
o
L
R
ﬁcular cardiomyopathy e163
is, which showed abnormal uptake in the bilateral hilar
ymph nodes (Fig. 4(b)). Because the patient was on the
aiting list for heart transplant, the diagnosis of sarcoido-
is was essential for considering a future immunosuppressant
rotocol after transplantation. Therefore, in addition to the
iagnostic ﬁnding of imaging, histological deﬁnitive diagno-
is was essential for this patient. Therefore, a biopsy of
he inguinal lymph node was performed, which revealed
umerous noncaseating epithelioid granulomas with multin-
clear giant cells consistent with sarcoidosis (Fig. 4(c)). The
-[18F]ﬂuoro-2-deoxy-D-glucose positron emission tomogra-
hy scanning (FDG-PET) demonstrated intense uptake in
he myocardium (Fig. 4(d-I)), and the patient was ﬁnally
iagnosed with cardiac sarcoidosis. Although mediastinal
ymphadenopathy is an important and useful ﬁnding to
iagnose cardiac sarcoidosis [1], mediastinal lymphadenopa-
hy was detected neither by FDG-PET nor by Gallium-67
cintigraphy in this patient. He started to be treated with
teroids for active cardiac sarcoidosis. After 1 month of
teroid administration, the abnormal uptake detected by
DG-PET disappeared (Fig. 4(d-I) and (d-II)). The frequency
f arrhythmia decreased after steroid therapy, however, his
ardiac function did not improve and he remains on the heart
ransplant waiting list.
iscussion
e experienced a patient, who was initially diagnosed
ith dilated phase of hypertrophic cardiomyopathy and
hen diagnosed with ARVC on account of echocardiographic
ndings of remarkable RV enlargement and decreased con-
raction. However, ﬁnally he was conﬁrmed to have cardiac
arcoidosis. The diagnosis of cardiac sarcoidosis was ﬁnally
ade on the basis of the pathological ﬁndings of the inguinal
ymph node and active uptake of the heart detected by
DG-PET. In this case, the abnormal uptake detected by FDG-
ET was diminished after adequate therapy such as steroid
dministration for sarcoidosis. FDG-PET scanning is a use-
ul tool not only for diagnosing cardiac sarcoidosis, but also
valuating effectiveness of treatment [2—4].
The echocardiographic manifestations of presumed car-
iac sarcoidosis are thinning of the basal septum, as
well-known feature, regional wall motion abnormali-
ies, pericardial effusion, and LV chamber dilatation with
ecreased systolic function. However, these representa-
ive features are not always seen in patients with cardiac
arcoidosis. Moreover, a deﬁnitive histological diagnosis of
ardiac sarcoidosis is extremely difﬁcult, because the granu-
omas of sarcoidosis are locally found within the myocardium
nd an endomyocardial biopsy may not prove the diagnosis
5].
Cardiac sarcoidosis mimicking ARVC is extremely rare,
lthough several authors have reported cardiac sarcoidosis
nvolving mainly RV or biventricles [6,7] such as seen in this
atient. ARVC would be a suspected diagnosis for a patient
ho has ventricular arrhythmias and generalized dilatation
r localized abnormalities of RV in the presence of preserved
V size and function. ARVC is a heart muscle disease affecting
V, rarely involving LV, and is pathologically characterized by
bro-fatty replacement of the myocardium [8].
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Figure 3 (a) Chest X-ray showing marked cardiomegaly with cardio-thoracic ratio of 81%. (b-I) Twelve-lead electrocardiogram
showing atrial ﬂutter with 2:1 atrio-ventricular conduction, low voltage in V1—4. (b-II) Twelve-lead electrocardiogram showing sinus
rhythm after cardioversion.
Figure 4 (a) Computed tomography scan of the chest. The arrows indicate marked bilateral hilar lymphadenopathy. (b) Gallium-
67 scintigraphy of the chest. The arrows indicate abnormal uptake in the bilateral hilar lymph nodes. (c) Photomicrograph of the
inguinal lymph node biopsy showing noncaseating epithelioid granuloma with multinuclear giant cells (hematoxylin and eosin stained
histological sections at 400×). (d-I) The 2-[18F]ﬂuoro-2-deoxy-D-glucose positron emission tomography scan demonstrating intense
uptake in the myocardium before steroid therapy. (d-II) The scan obtained after steroid therapy, which showed disappearance of
abnormal uptake.
entriCardiac sarcoidosis masquerading as arrhythmogenic right v
Initially, the patient in this report was diagnosed with
dilated phase of hypertrophic cardiomyopathy, and then
diagnosed as ARVC with LV involvement. Sen-Chowdhry et
al. [9] demonstrated that late enhancement of gadolinium-
enhanced cardiovascular MRI is suggestive of LV involvement
in ARVC, and 84% of patients diagnosed with ARVC have
LV involvement. The patient in this report also had late
enhancement in biventricles on gadolinium-enhanced car-
diovascular MRI, which was interpreted as supporting
evidence for diagnosing this patient as having ARVC at
this point. Several previous papers reported that cardiac
sarcoidosis in its early stage mimics hypertrophic cardiomy-
opathy [10]. Due to the relatively well-preserved wall
thickness despite of severe LV dysfunction, the patient was
initially diagnosed as having dilated phase of hypertrophic
cardiomyopathy. However, we might have been able to
suspect cardiac sarcoidosis at this point in hindsight. LV con-
centric hypertrophy initially shown in this patient would be
a sign of early stage of cardiac sarcoidosis.
We emphasize the need to consider cardiac sarcoido-
sis in the differential diagnosis of patients who present
with structural abnormalities of RV and who are suspected
of having ARVC. In addition, it should be recognized that
RV involvement is one of the manifestations of cardiac
sarcoidosis.
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